PMC:7696151 / 69510-69824 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1974","span":{"begin":60,"end":68},"obj":"Species"},{"id":"1993","span":{"begin":137,"end":147},"obj":"Chemical"},{"id":"2001","span":{"begin":74,"end":103},"obj":"Disease"}],"attributes":[{"id":"A1974","pred":"tao:has_database_id","subj":"1974","obj":"Tax:9606"},{"id":"A1993","pred":"tao:has_database_id","subj":"1993","obj":"MESH:D000069285"},{"id":"A2001","pred":"tao:has_database_id","subj":"2001","obj":"MESH:D001171"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In a multicenter open-label clinical trial, performed on 60 patients with juvenile idiopathic arthritis for 54 weeks, the combination of infliximab monoclonal antibodies with a conventional antirheumatic drug provided the better response in terms of disease inactivation with respect to DMARD administration [128]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T128","span":{"begin":74,"end":103},"obj":"Phenotype"}],"attributes":[{"id":"A128","pred":"hp_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/HP_0005681"}],"text":"In a multicenter open-label clinical trial, performed on 60 patients with juvenile idiopathic arthritis for 54 weeks, the combination of infliximab monoclonal antibodies with a conventional antirheumatic drug provided the better response in terms of disease inactivation with respect to DMARD administration [128]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T443","span":{"begin":0,"end":314},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In a multicenter open-label clinical trial, performed on 60 patients with juvenile idiopathic arthritis for 54 weeks, the combination of infliximab monoclonal antibodies with a conventional antirheumatic drug provided the better response in terms of disease inactivation with respect to DMARD administration [128]."}